Melanoma Institute Australia

Housed on the Mater campus The Poche Centre is home to Melanoma Institute Australia, the largest single tumour cancer centre in Australia. It is an integrated facility and expands existing Mater cancer services whilst providing the best possible care for melanoma patients.

Live streaming of surgery from theatre to the Reg Richardson auditorium at The Poche Centre provides students with the ability to study surgery in the new state-of-the-art teaching auditorium. The auditorium seats 100 people and boasts high definition presentation and digital recording equipment.

Clinicians and researchers

The Poche Centre houses over 70 clinicians, clinical trials staff and researchers, plus the largest melanoma patient database and integrated tumour bank in the world. The institute's multidisciplinary treatment team is all under the one roof with specialists in surgical oncology, head and neck surgery, plastic surgery, medical and radiation oncologists.

Clinical trials

Clinical trials are an important part of melanoma research with over 1,000 patients participating at The Poche Centre this year. In order to advance studies into the cause of melanoma and treatment it is necessary to recruit large numbers of people from the community. Patients may be eligible and are encouraged to participate.

Melanoma Institute Australia recently sent a team to present at The American Society of Clinical Oncology (ASCO) in Chicago including the institute's Co-Director of Research, Professor Rick Kefford, who leads the Australian contribution to the worldwide study into drug therapies that target melanoma genes. Major advances are now being made in 'unlocking' the molecular vulnerabilities of melanoma to targeted drug attack.

Melanoma Institute Australia is a not-for profit organisation dedicated to minimising the impact of melanoma through innovative research, treatment and education programs. It evolved from the Sydney Melanoma Unit, established in the early 1960s to provide a world class treatment facility for melanoma patients. Read more…